Daiichi Sankyo Aims For Flu Drug NDA In Japan In 2009
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo announced a plan to apply for a new drug application with Japan's Ministry of Health, Labor and Welfare within the year. According to the company, Phase II/III results for new flu drug CS-8958 showed promising results, especially when used in children under the age of nine, who have shown better results compared to Tamiflu (oseltamivir). Daiichi Sankyo said no adverse effects have been identified during the trials. CS-8958 is a long-lasting nasal inhalation flu drug and can be used to patients who need both Tamiflu and Relenza (zanamivir). (Click here for more - Japanese language
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”